Assessing Function Before Initiating GLP-1 Therapy in Older Adults

Editor's Note: The Medicare GLP-1 Bridge is an evolving federal demonstration, currently authorized through December 31, 2027. The Part D portion of the successor BALANCE Model has been delayed and no replacement has been finalized. This information is subject to change based on upcoming CMS guidance and federal rulemaking.

Key Takeaways:

• Coverage eligibility is defined by body mass index and comorbidity. It includes no assessment of muscle mass, physical function, frailty, or nutritional status.
• Patients aged 75 and older are nearly absent from the pooled weight-reduction trials for this drug class, so prescribing in the oldest patients is extrapolation.
• For some older adults with obesity, preserving muscle mass and functional capacity is the appropriate therapeutic goal rather than weight reduction.

Medicare coverage for weight management under the GLP-1 Bridge demonstration is authorized through December 31, 2027, and the eligible population is broader than many clinicians assume. Eligibility, however, answers a payer question rather than a clinical one. Nothing in the criteria asks whether a particular older patient is a good candidate for intentional weight loss, and for a subset of Medicare-age patients the answer is no.^1,2

What eligibility does not ask

The demonstration's criteria are built from body mass index (BMI) and comorbidity. A BMI of 35 or above qualifies with no additional condition required, and lower thresholds qualify when a specified cardiometabolic comorbidity is present. There is no measure of muscle mass, physical function, frailty, or nutritional status anywhere in that framework.¹

The omission matters more in older adults than in any other group. The European Association for the Study of Obesity (EASO) position statement on obesity in older adults concludes that BMI alone is insufficient for diagnosing obesity in this population, because it cannot discriminate between fat mass and fat-free mass. Two patients with identical BMI values can differ substantially in skeletal muscle, and that difference changes what treatment should be trying to achieve.³

Screening function at the visit

EASO recommends assessing function directly, using measures that fit inside a routine visit. Handgrip strength below 16 kg in women or 27 kg in men, a 5-times-sit-to-stand time above 15 seconds, a gait speed of 0.8 m/s or less, or a Short Physical Performance Battery (SPPB) score of 8 or less each identify reduced functional reserve.³

These measures matter because incretin-based weight reduction is not selective for fat. About 25 percent of total weight lost is attributable to lean mass.⁴

Evidence within the class is not uniform. A 24-month cohort of adults aged 65 and older receiving glucagon-like peptide-1 (GLP-1) receptor agonist therapy found significant declines in appendicular skeletal muscle mass index (ASMI), handgrip strength, and gait speed relative to matched controls.⁵

A post hoc analysis of trials of a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist found no disproportionate lean-mass loss in participants aged 65 and older compared with younger participants. Neither finding has been replicated prospectively in adults above 75.⁴

The evidence gap above 75

The trial evidence thins sharply at the top of the age range. In the pooled weight-reduction studies supporting one agent in this class, 13 patients – 0.5 percent of those treated – were aged 75 or older. For another agent, 23 patients, or 1 percent, were 75 or older across the injection trials, and 5 patients, or 2 percent, in the oral trial.^6,7

A cardiovascular outcomes trial did enroll 703 patients aged 75 and older, and in that trial patients in this age group reported more serious adverse reactions overall than younger adults.7
EASO states that evidence in adults aged 75 and older is scarce, and identifies a mechanism that is easy to overlook: Gastrointestinal effects may amplify the anorexia of aging, a condition already common above 75. Prescribing in this group is extrapolation, and it warrants closer follow-up than a younger patient starting the same therapy.³

When stability is the goal

For some older adults with obesity, the appropriate therapeutic goal is not only weight reduction. EASO recommends that goals in this population center on preserving muscle mass, maintaining functional capacity, and improving quality of life rather than weight loss alone.³

In a patient with reduced grip strength, slow gait speed, unintentional weight loss at baseline, or limited life expectancy, weight stability paired with resistance exercise and adequate protein intake is a defensible plan.

Where therapy is appropriate, protein intake of 1.0 to 1.2 g/kg per day distributed across 3 main meals supports muscle preservation, though intake above 1.2 g/kg should be avoided in impaired renal function. The American College of Physicians advises clinicians to counsel patients about possible unintended effects of weight loss, including nutritional deficiencies and adverse changes in body composition, particularly in older adults.^3,8

The practical step is a small one: Measure function before writing the prescription rather than after the first refill. Ongoing assessments are recommended after prescribing.

Coverage eligibility establishes that a patient may be treated. It does not establish that a patient should be.